Grufity logo
Grufity logo
PBLA

PBLA - Panbela Therapeutics Inc. Stock Price, Fair Value and News

$0.010.00 (0.00%)
Market Closed as of 15 Jun 2026, 04:00 pm ET

Price Targets

PBLA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PBLA Price Action

Trailing 12 Months

-96%

PBLA RSI Chart

PBLA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PBLA Valuation

Market Cap

48.5K

Price/Earnings (Trailing)

0

Price/Sales (Trailing)

0.04

EV/EBITDA

-0.11

Price/Free Cashflow

0

PBLA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

PBLA Fundamentals

PBLA Revenue

PBLA Earnings

PBLA Profitability

Free Cashflow Yield

-32.0K%

PBLA Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
20151.4M1.4M--
20141.0M1.1M1.1M1.4M
20131.2M1.2M1.1M981.1K
2012833.0K966.2K1.1M1.2M
2011---699.8K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Panbela Therapeutics Inc.

PBLA
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with cancer. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin (SBP-101). The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
 CEO
 WEBSITEpanbela.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES6

Panbela Therapeutics Inc. Frequently Asked Questions

PBLA is the stock ticker symbol of Panbela Therapeutics Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jun 12 2026, market cap of Panbela Therapeutics Inc. is 48.55 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jun 12 2026, PBLA's PE ratio (Price to Earnings) is 0 and Price to Sales (PS) ratio is 0.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PBLA PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Panbela Therapeutics Inc. has provided -0.774 (multiply by 100 for percentage) rate of return.